Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.54 |
| ▸ | STS | P08842 | 5/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13261261 | 0.83 | STS (0.54) | GPR119STSPTPN2PTPN1PTPN6 | |
| SCHEMBL29242060 | 0.80 | POLB (0.56) | POLBGPR119KMT2A | |
| SCHEMBL406827 | 0.80 | GPR119 (0.62) | POLBGPR119STSPTPN2PTPN1 | |
| SCHEMBL3813527 | 0.79 | STS (0.62) | POLBGPR119STSPTPN2PTPN1 | |
| SCHEMBL25452815 | 0.79 | STS (0.51) | GPR119STSPTPN2PTPN1PTPN6 | |
| SCHEMBL27061355 | 0.78 | POLB (0.54) | POLBGPR119 | |
| SCHEMBL30476370 | 0.78 | ALDH1A1 (0.54) | POLBGPR119USP30NPC1RAB9A | |
| SCHEMBL20817804 | 0.78 | ALDH1A1 (0.54) | POLBGPR119USP30NPC1RAB9A | |
| SCHEMBL9003283 | 0.78 | STS (0.54) | GPR119STSPTPN2PTPN1PTPN6 | |
| SCHEMBL15566640 | 0.78 | STS (0.54) | GPR119STSPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2020063760-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | POLB 2889/4885GPR119 1235/4885STS 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.